Abstracts tagged "Crystal-induced arthritis"

Abstract Number: 0661 • ACR Convergence 2020
Genomic Regions Jointly Associated with eGFR and Serum Urate: Implications for Shared Genetic Etiology of Hyperuricemia and Chronic Kidney Disease
Nick Sumpter¹, Alexa Lupi², Megan Leask³, Tony Merriman⁴, Ana Vazquez² and Richard Reynolds¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Michigan State University, East Lansing, MI, ³University of Otago, Dunedin, Otago, New Zealand, ⁴University of Otago, Dunedin, New Zealand
Background/Purpose: Gout and hyperuricemia (HU), serum urate (SU) > 6.8 mg/dL, often present in the context of chronic kidney disease. It has long been known…
Abstract Number: 0670 • ACR Convergence 2020
Risk Factors for Pseudogout: An Electronic Medical Record Case-Control Study
Sara Tedeschi¹, Kazuki Yoshida¹, Weixing Huang² and Daniel H. Solomon¹, ¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: Prior studies of calcium pyrophosphate crystal deposition disease (CPPD) epidemiology either focused on the entire spectrum of CPPD or identified patients with its acute…
Abstract Number: 0676 • ACR Convergence 2020
Surveying Practicing Rheumatologists Regarding Gout Management and Barriers in Gout Care
Joshua Gavin¹, Yashswee KC², Evan Dombrosky³, Nehal Shah⁴ and Youssef Roman⁴, ¹Virginia Commonwealth University School of Medicine, Richmond, ²Virginia Commonwealth University School of Medicine, Henrico, VA, ³Virginia Commonwealth University School of Medicine, Glen Allen, VA, ⁴Virginia Commonwealth University School of Medicine, Richmond, VA
Background/Purpose: The management of gout is heterogeneous across specialties and clinical settings. Gout has been demonstrated to be one of the most poorly managed conditions…
Abstract Number: 0685 • ACR Convergence 2020
The Impact of Azathioprine on the Frequency of Persistent Responsiveness to Pegloticase in Patients with Chronic Refractory Gout
Herbert S. Baraf¹, Hope Rainey², Peter Lipsky² and Peter Lipsky³, ¹The Ctr for Rheumatology and Bone Research, Wheaton, MD, ²AMPEL BioSolutions LLC., Charlottesville, VA, ³RILITE Foundation, Charlottesville, VA
Background/Purpose: Pegloticase is a mammalian recombinant uricase coupled to monomethoxy polyethylene glycol that is approved in the US for treatment of patients with chronic refractory…
Abstract Number: 0687 • ACR Convergence 2020
Musculoskeletal Manifestations in Patients with CD73 Deficiency
Cornelia Cudrici¹, Kam Newman², Deepak Lakshmipathy¹, Elisa Ferrante¹, Rebecca Huffstutler¹, Katherine Carney¹, Blas Betancourt², Markku Miettinen³, James Katz⁴, Leon Nesti⁵, Han Wen¹, Manfred Boehm⁶ and Alessandra Brofferio¹, ¹National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³National Cancer Institute, National Institutes of Health, Bethesda, MD, ⁴NIH NIAMS, Bethesda, MD, ⁵Clinical and Experimental Orthopaedics, Walter Reed National Military Medical Center, Bethesda, MD, ⁶Center for Molecular Medicine, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Arterial calcification due to deficiency of CD73 (ACDC) is a hereditary autosomal recessive ectopic mineralization syndrome caused by loss-of-function mutations in the 5'-nucleotidase Ecto…
Abstract Number: 1573 • ACR Convergence 2020
Gout as an Immune-Related Adverse Event from Immune Checkpoint Inhibitors
Kevin Lee¹, Carrie Ye² and Shokrollah Elahi³, ¹Internal Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, University of Alberta, Edmonton, AB, Canada, ³Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) are novel treatments approved for various tumours including melanoma, lung and kidney. By interacting with immunoregulatory molecules (programmed death-1 (PD-1),…
Abstract Number: 0445 • ACR Convergence 2020
Dual-Energy CT in Gout Patients: Do All Color-Coded Lesions Actually Represent Monosodium Urate Crystals?
Sara Christiansen¹, Felix Müller², Mikkel Østergaard³, Ole Slot¹, Jakob Møller², Henrik Børgesen², Kasper Gosvig² and Lene Terslev⁴, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup., Glostrup, Denmark, ²Department of Radiology, Herlev and Gentofte Hospital, Herlev, Denmark, ³Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup., Copenhagen, Denmark
Background/Purpose: Dual-Energy CT (DECT) can acknowledge differences in tissue compositions and can color-code tissues with specific features including monosodium urate (MSU) crystals. However, when evaluating…
Abstract Number: 343 • 2019 ACR/ARP Annual Meeting
Emergency Department Length of Stay in Patients with Acute Gout
Nadine Mbuyi¹, Steven Reinert ², Ross Hilliard ³, Anthony Reginato ³ and Deepan Dalal ³, ¹George Washington University, Washington, DC, ²Lifespan Health System, Providence, RI, ³Brown University, Rhode Island Hospital, Providence, RI
Background/Purpose: Emergency department (ED) visits for acute gout increased by approximately 20% between 2006 and 2014 in the United States. (1) Reducing ED length of stay…
Abstract Number: 354 • 2019 ACR/ARP Annual Meeting
Evaluation of Opioid Analgesia in Hospitalized Patients with Acute Crystal Induced Arthritis
Sukhraj Singh¹, Anthony Ocon ¹, Mark Riley ², Jennifer Tchervenkov ¹ and Ruben Peredo-Wende ¹, ¹Albany Medical Center, Albany, NY, ²Albany Medical Center, Albany
Background/Purpose: The Opioid Epidemic has been declared a public health emergency since 2017. The use of opioids in the acute crystal induced arthritis (ACIA) population…
Abstract Number: 194 • 2018 ACR/ARHP Annual Meeting
A Survey on Gout-Related Knowledge Among Internal Medicine Residents
Sreelakshmi Panginikkod¹, Ahmad Raja², Ehsan Rajabirostami¹, Roshanak Habibi¹, Rasiya Hashim³, Sumia Matin Afridi⁴, Alvaro Altamirano Ufion⁵ and Venu Pararath Gopalakrishnan¹, ¹Internal Medicine, Presence Saint Francis Hospital, Evanston, IL, ²Presence Saint Francis Hospital, Evanston, IL, ³Presence Saint Joseph Hospital, Evanston, IL, ⁴Florida Hospital Orlando, Orlando, FL, ⁵Internal Medicine, Advocate Illinois Masonic Medical Center, Chicago, IL
Background/Purpose: The prevalence of gout has risen in recent decades despite advancements in therapeutic options due to several reasons, including lack of adherence to treatment…
Abstract Number: 870 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Burden of Gout in 2017 from the United States
Puja P. Khanna¹, Douglas C.A. Taylor², An-Chen Fu² and Robert Morlock³, ¹University of Michigan, Ann Arbor, MI, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA, ³YourCareChoice, Ann Arbor, MI
Background/Purpose: Gout is reported to impact 3.9% of the US adult population (Zhu. Arthritis Rheum 2011;63:3136-41). Treatment encompasses controlling acute attacks (flares) and, dependent on…
Abstract Number: 1030 • 2018 ACR/ARHP Annual Meeting
Parenteral Injection of Human Adipose-Derived Mesenchymal Stem Cells Attenuates Inflammation in an Acute Model of Gouty Arthritis
Juan Pablo Medina¹, Sandra Perez-Baos¹, Esperanza Naredo², Alberto Lopez-Reyes³, Gabriel Herrero-Beaumont⁴ and Raquel Largo⁴, ¹Joint and Bone Research Unit, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain, ²Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ³Synovial fluid analysis department, Instituto Nacional de Rehabilitación, Mexico City, Mexico, ⁴Bone and Joint Research Unit, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain
Background/Purpose: The regenerative and immunomodulatory properties of Adipose-Derived Mesenchymal Stem Cells (ASCs) make them a potential therapeutic approach for the treatment of chronic inflammatory diseases,…
Abstract Number: 1260 • 2018 ACR/ARHP Annual Meeting
Predictors of Hospitalization Due to Acute Gout: A Retrospective Cohort Study
Nadine Mbuyi¹, Isha Shah², Steven Reinert³, Grayson Baird⁴, Pieusha Malhotra⁵, Ross Hilliard⁶ and Deepan Dalal⁷, ¹Rheumatology, The Warren Alpert Medical School of Brown University, Providence, RI, ²Internal Medicine, The Warren Alpert Medical School of Brown University, Providence, RI, ³Lifespan Information Services, Lifespan Information Services, Providence, RI, Providence, RI, ⁴Department of Biostatistics, Lifespan, Rhode Island Hospital, Providence, RI, ⁵Rheumatology, Roger William Medical Center, Providence, RI, Providence, RI, ⁶Medicine, The Warren Alpert Medical School of Brown University, Providence, RI, ⁷Medicine/Rheumatology, The Warren Alpert Medical School of Brown University, Providence, RI
Background/Purpose: Despite effective treatments, hospitalization due to acute gout is increasing and is financially burdensome. Prior studies have primarily attributed the increased rate of gout…
Abstract Number: 1268 • 2018 ACR/ARHP Annual Meeting
Assessment of the Persistence of Crystals Under Polarised Light Microscopy in Stored Synovial Fluid Samples
Sonia Pastor¹, Rocio Caño², Silvia Gomez-Sabater² and Mariano Andrés^1,3, ¹Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain, ²Seccion de Reumatologia, Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain, ³Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
Background/Purpose: Lacking an immediate access to a polarized light microscope is sometimes used to justify the clinical diagnosis of crystal-related arthritis. Some studies have assessed…
Abstract Number: 1273 • 2018 ACR/ARHP Annual Meeting
What Did Patients from the US Think about Their Gout in 2017?
Puja P. Khanna¹, Douglas C.A. Taylor², An-Chen Fu² and Robert Morlock³, ¹University of Michigan, Ann Arbor, MI, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA, ³YourCareChoice, Ann Arbor, MI
Background/Purpose: The impact of chronic gout and acute flares on daily activities is severely limiting. Yet only 40% of gout patients receive urate-lowering therapy (ULT),…